Kobayashi Pharmaceutical ... (KBYPF)
Kobayashi Pharmaceutical Statistics
Share Statistics
Kobayashi Pharmaceutical has 74.34M shares outstanding. The number of shares has increased by -9.03% in one year.
| Shares Outstanding | 74.34M |
| Shares Change (YoY) | -9.03% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 43.48 and the forward PE ratio is null. Kobayashi Pharmaceutical's PEG ratio is -0.88.
| PE Ratio | 43.48 |
| Forward PE | n/a |
| PS Ratio | 2.64 |
| Forward PS | n/a |
| PB Ratio | 2.05 |
| P/FCF Ratio | -28.45 |
| PEG Ratio | -0.88 |
Enterprise Valuation
Kobayashi Pharmaceutical has an Enterprise Value (EV) of 387.69B.
| EV / Sales | 2.34 |
| EV / EBITDA | 17.65 |
| EV / EBIT | 34.47 |
| EV / FCF | -25.2 |
Financial Position
The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.
| Current Ratio | 3.11 |
| Quick Ratio | 2.59 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | -0.05 |
| Interest Coverage | 887.86 |
Financial Efficiency
Return on Equity is 4.72% and Return on Invested Capital is 8.21%.
| Return on Equity | 4.72% |
| Return on Assets | 3.79% |
| Return on Invested Capital | 8.21% |
| Revenue Per Employee | $45,809,128.63 |
| Profits Per Employee | $2,784,785.62 |
| Employee Count | 3,615 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 3.23 |
Taxes
| Income Tax | 3.84B |
| Effective Tax Rate | 27.61% |
Stock Price Statistics
The stock price has increased by 15.2% in the last 52 weeks. The beta is 0.47, so Kobayashi Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.47 |
| 52-Week Price Change | 15.2% |
| 50-Day Moving Average | 37.43 |
| 200-Day Moving Average | 35.28 |
| Relative Strength Index (RSI) | 93.28 |
| Average Volume (20 Days) | 11 |
Income Statement
In the last 12 months, Kobayashi Pharmaceutical had revenue of 165.6B and earned 10.07B in profits. Earnings per share was 135.42.
| Revenue | 165.6B |
| Gross Profit | 87.6B |
| Operating Income | 24.86B |
| Net Income | 10.07B |
| EBITDA | 21.96B |
| EBIT | 13.94B |
| Earnings Per Share (EPS) | 135.42 |
Balance Sheet
The company has 50.87B in cash and 846M in debt, giving a net cash position of 50.03B.
| Cash & Cash Equivalents | 50.87B |
| Total Debt | 846M |
| Net Cash | 50.03B |
| Retained Earnings | 208.24B |
| Total Assets | 265.37B |
| Working Capital | 98.05B |
Cash Flow
In the last 12 months, operating cash flow was 11.25B and capital expenditures -26.63B, giving a free cash flow of -15.38B.
| Operating Cash Flow | 11.25B |
| Capital Expenditures | -26.63B |
| Free Cash Flow | -15.38B |
| FCF Per Share | -206.93 |
Margins
Gross margin is 52.9%, with operating and profit margins of 15.01% and 6.08%.
| Gross Margin | 52.9% |
| Operating Margin | 15.01% |
| Pretax Margin | 8.4% |
| Profit Margin | 6.08% |
| EBITDA Margin | 13.26% |
| EBIT Margin | 15.01% |
| FCF Margin | -9.29% |
Dividends & Yields
KBYPF pays an annual dividend of $0.58, which amounts to a dividend yield of 0.83%.
| Dividend Per Share | $0.58 |
| Dividend Yield | 0.83% |
| Dividend Growth (YoY) | 15.65% |
| Payout Ratio | 65.15% |
| Earnings Yield | 2.3% |
| FCF Yield | -3.51% |
Analyst Forecast
Currently there are no analyst rating for KBYPF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 26, 2017. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 26, 2017 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 2.48 |
| Piotroski F-Score | 4 |